Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia

Amberbir, Alemayehu; Woldemichael, Kifle; Getachew, Sofonias; Girma, Belaineh; Deribe, Kebede
January 2008
BMC Public Health;2008, Vol. 8 Issue 1, p265
Academic Journal
Background: The devastating impact of AIDS in the world especially in sub-Saharan Africa has led to an unprecedented global effort to ensure access to antiretroviral (ARV) drugs. Given that medication-taking behavior can immensely affect an individual's response; ART adherence is now widely recognized as an 'Achilles heel' for the successful outcome. The present study was undertaken to investigate the rate and predictors of adherence to antiretroviral therapy among HIV-infected persons in southwest Ethiopia. Methods: The study was conducted in the antiretroviral therapy unit of Jimma University Specialized Hospital. A prospective study was undertaken on a total of 400 HIV infected person. Data were collected using a pre-tested interviewer-administered structured questionnaire at first month (M0) and third month (M3) follow up visits. Results: A total of 400 and 383 patients at baseline (M0) and at follow up visit (M3) respectively were interviewed. Self-reported dose adherence in the study area was 94.3%. The rate considering the combined indicator (dose, time and food) was 75.7%. Within a three month follow up period, dose adherence decreased by 2% and overall adherence rate decreased by more than 3%. Adherence was common in those patients who have a social support (OR, 1.82, 95%CI, 1.04, 3.21). Patients who were not depressed were two times more likely to be adherent than those who were depressed (OR, 2.13, 95%CI, 1.18, 3.81). However, at the follow up visit, social support (OR, 2.42, 95%CI, 1.29, 4.55) and the use of memory aids (OR, 3.29, 95%CI, 1.44, 7.51) were found to be independent predictors of adherence. The principal reasons reported for skipping doses in this study were simply forgetting, feeling sick or ill, being busy and running out of medication in more than 75% of the cases. Conclusion: The self reported adherence rate was high in the study area. The study showed that adherence is a dynamic process which changes overtime and cannot reliably be predicted by a few patient characteristics that are assumed to vary with time. Adherence is a process, not a single event, and adherence support should be integrated into regular clinical follow up.


Related Articles

  • Consequences of HIV testing without consent. Obi, Samuel N.; Ifebunandu, Ngozi A. // International Journal of STD & AIDS;Feb2006, Vol. 17 Issue 2, p93 

    The objective of this study is to explore the HIV-infected individuals' experience with HIV testing, counselling, disclosure of diagnosis and subsequent life events following diagnosis. The method used is a questionnaire survey of 340 consecutive HIV-positive victims, seen in two health...

  • First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. Pere Domingo; Ignacio Suárez-Lozano; Ferran Torres; Ramón Teira; José Lopez-Aldeguer; Francesc Vidal; Agustín Muñoz; Pompeyo Viciana; Fernando Lozano; Antonio Vergara; Bernadino Roca; Ma Luisa García Alcalde; Jaime Cosín; Alberto Terrón; Ma José Galindo; Paloma Geijo; Esteban Ribera; Juan Gonzalez; Trinitario Sanchez; Juan Ramón Lacalle // Journal of Antimicrobial Chemotherapy (JAC);Jun2008, Vol. 61 Issue 6, p1348 

    Background Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for combination first-line therapy, although information on direct comparisons between them is scarce. A retrospective longitudinal study from the VACH cohort comparing both regimens was performed. Methods...

  • Natural History of Patients with Low-Level HIV Viremia on Antiretroviral Therapy. Re III., Vincent Lo; Gasink, Leanne; Kostman, Jay R.; Leonard, Debra; Gross, Robert // AIDS Patient Care & STDs;Aug2004, Vol. 18 Issue 8, p436 

    Ultrasensitive assays for HIV RNA have identified a significant number of patients with persistent low-level viremia despite antiretroviral therapy. The clinical implications of maintaining antiretroviral therapy during low-level HIV viremia remain unclear. The primary objective of this study...

  • Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naive to Antiretrovirals. Torti, Carlo; Quiros-Roldan, Maria Eugenia; Cologni, Giuliana; Nichelatti, Michele; Ceresoli, Francesca; Pinti, Marcello; Nasi, Milena; Cossarizza, Andrea; Lapadula, Giuseppe; Costarelli, Silvia; Manca, Nino; Gargiulo, Franco; Magoni, Michele; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p43 

    (i) To compare early decrease of HIV plasma viral load (pVL) after two standard combinations of highly active antiretroviral therapy (HAART). (ii) To evaluate variations of proviral HIV-DNA load on conditions of sustained pVL undetectability. Two different sub-studies of a multicentre...

  • A Comparison of the Therapeutic Plan Costs in the Treatment of HIV-Positive Patients. Sabbatani, S. // Clinical Drug Investigation;2003, Vol. 23 Issue 7, p473 

    Objective: To determine the cost of each therapeutic protocol (TP) used for HIV-positive patients and to identify the most frequently adopted one by relating it to the cost and by identifying the drug (drugs) that is more competitive in relation to expense. Setting: Infectious Disease Department...

  • Spotlight on Mammalian Cell-Derived Somatropin in HIV-Associated Wasting1. Goldsmith, David R.; Wagstaff, Antona J. // BioDrugs;2006, Vol. 20 Issue 3, p191 

    HIV-associated wasting, characterized by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy. Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant...

  • Antiretroviral Drugs in Pediatric HIV-Infected Patients. Phelps, B. Ryan; Rakhmanina, Natella // Pediatric Drugs;2011, Vol. 13 Issue 3, p175 

    Antiretroviral (ARY) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HLV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress...

  • Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

    Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

  • CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Agan, Brian K.; Camargo, Jose F.; Weijing He; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Eron, Joseph; Clark, Robert A.; Frost, Simon; Martin, Jeffrey; Ahuja, Seema S.; Deeks, Steven G.; Little, Susan; Richman, Douglas; Hecht, Frederick M.; Dolan, Matthew J. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p413 

    The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics